Several therapeutic approaches for NASH are currently under evaluation including PPARα and FXR agonists.45 Results from the FLINT trial have highlighted OCA as a promising therapeutic agent in NASH17 and Mudaliar et al.46 have documented its efficacy and safety in the treatment of patients with NAFLD and diabetes. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.